{"name":"Generic APIs","slug":"divi","ticker":"DIVISLAB.NS","exchange":"NSE","domain":"divislabs.com","description":"Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.","hq":"Hyderabad, India","founded":1995,"employees":"10542","ceo":"Kiran S. Divi","sector":"API / CRAMS / Nutraceuticals","stockPrice":5882,"stockChange":32,"stockChangePercent":0.55,"marketCap":"$1.6T","metrics":{"revenue":103139999744,"revenueGrowth":12.3,"grossMargin":61.7,"rdSpend":0,"netIncome":24789999616,"cash":32610000896,"dividendYield":0.52,"peRatio":62.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lisinopril patent cliff ($100M at risk)","drug":"Lisinopril","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Atorvastatin patent cliff ($200M at risk)","drug":"Atorvastatin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Generic APIs Reports 15% YoY Growth in Q3 FY24","summary":"Generic APIs announced its Q3 FY24 earnings, reporting a 15% year-over-year growth in revenue. The company attributed the growth to increased demand for its APIs and CRAMS.","drugName":"","sentiment":"positive"},{"date":"2023-08-22","type":"deal","headline":"Generic APIs Partners with US-Based Pharmaceutical Company","summary":"Generic APIs announced a partnership with a US-based pharmaceutical company to supply its APIs for a new drug development project.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFB4QW5EdHRvOGtlWjN2Qzh3dXBQb3kwQnV6YjR6S0pnOWFIRDA1YXVDNnFVZGNUM3RodEFXUmZKbWZkU2ZzbGFGQ1pHY2RfRnZNQlh1YUprREpseW1yd1V3MWE4SzJ3WjFl?oc=5","date":"2024-09-18","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Laurus Labs Limited (LAURUSLABS.NS) company profile and facts - Yahoo Finance Singapore","headline":"Laurus Labs Limited (LAURUSLABS.NS) company profile and facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE82X0JMTVZkOUhDVWJYa0dvYnlGVnc1bkxQbERJbkRlUzF2YWx1SlBzMDVsQjFZREdGZVBYbzI4SlJtN1JfdURyaEpWdlB6bjZsNVFVRGJUMnNpUjlZelE?oc=5","date":"2022-05-02","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Laurus Labs Limited (LAURUSLABS.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Laurus Labs Limited (LAURUSLABS.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE52Rmh5MGJHY1BQSm92dG9xSDFoQ0xXQ3diekY5Q054YjEwQUlfWEFOOVFXaXB2cFV3UEF2dGI1UzJRcl9NUllwdFMyYVFLWjZOYnBZUlUwNE1ZSE1kSlE?oc=5","date":"2017-06-15","type":"pipeline","source":"Yahoo Finance Australia","summary":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE44YlBfNU9saEFFLTNUZFl0TmpMNDZyeGxyUUlDbG5BZHJvVHlpNFZhNW9iQjk1TEVyMHgtdEZzRERxeWtEbXJweGRQWS1mT3FLWFR1cEhBNHk?oc=5","date":"2017-06-05","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Biocon Limited (BIOCON.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Biocon Limited (BIOCON.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFA3WVMyQlFOU3BRNndJeHAwTVZQbjRsajAwN3BSamVKX2g4MTBHY3FIbmxVblJDTS1kVksxVUtld3R6bllJck5uWTdpZ0VRLTZjZEFnMmdfaw?oc=5","date":"2017-05-31","type":"pipeline","source":"Yahoo Finance Australia","summary":"Lupin Limited (LUPIN.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Lupin Limited (LUPIN.NS) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Lisinopril","drugSlug":"lisinopril","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Atorvastatin","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Aurobindo Pharma","Cipla","Sun Pharmaceutical"],"therapeuticFocus":["Cardiovascular","Diabetes"],"financials":null,"yahoo":{"currentPrice":5882,"previousClose":5850,"fiftyTwoWeekHigh":7071.5,"fiftyTwoWeekLow":5231.6,"fiftyTwoWeekRange":"5231.6 - 7071.5","fiftyDayAverage":6159.54,"twoHundredDayAverage":6319.98,"beta":0.19,"enterpriseValue":1519950626816,"forwardPE":50.3,"priceToBook":10.12,"priceToSales":15.14,"enterpriseToRevenue":14.74,"enterpriseToEbitda":45.2,"pegRatio":0,"ebitda":33629999104,"ebitdaMargin":32.6,"freeCashflow":0,"operatingCashflow":0,"totalDebt":900000000,"debtToEquity":0.6,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"2.5 - Hold","recommendationKey":"hold","numberOfAnalysts":30,"targetMeanPrice":6895.53,"targetHighPrice":9140,"targetLowPrice":5140,"dividendRate":30,"payoutRatio":0.32,"fiveYearAvgDividendYield":1.14,"exDividendDate":1753401600,"insiderHeldPercent":52,"institutionHeldPercent":28.6,"sharesOutstanding":265468580,"floatShares":117721970,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":93.6,"epsForward":116.89,"revenuePerShare":388.48,"bookValue":580.95,"officers":[{"age":49,"name":"Dr. Kiran Satchandra Divi B. Pharm., M.Pharm","title":"CEO & Whole-Time Director"},{"age":67,"name":"Mr. Venkata Ramana Nimmagadda B.Sc.(Chem)","title":"Executive Director"},{"age":74,"name":"Dr. Murali Krishna Prasad Divi M. Pharm, Ph.D.","title":"MD & Executive Director"},{"age":63,"name":"Dr. Devendra Rao Sureddy M.Sc.","title":"Whole-Time Director (Manufacturing)"},{"age":42,"name":"Ms. Nilima Prasad Divi","title":"Whole-time Director, Chief Control Officer & Director of Commercial"},{"age":64,"name":"Mr. Venkatesa Perumallu Pasumarthy B.Com., F.C.A.","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Manoranjan  Jasti","title":"Chief Information Officer"},{"age":null,"name":"Mr. M. Satish Choudhury","title":"Company Secretary & Compliance Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.divislabs.com","phone":"91 40 6696 6300"}}